3 transcripts
ALKS
Earnings call transcript
NASDAQ
2024 Q2
24 Jul 24
on this metric as the key area for differentiation in NT1? Or do you think that it's really more about a broader risk-benefit evaluation and having
ALKS
Earnings call transcript
NASDAQ
2024 Q1
1 May 24
pharmacy benefit manager to improve formulary positioning. This contracting is not expected to significantly impact our anticipated gross to net
ALKS
Earnings call transcript
NASDAQ
2023 Q4
15 Feb 24
recorded a net tax benefit of $97.6 million, driven primarily by the partial release of a valuation allowance related to our Irish net operating loss
- Prev
- 1
- Next